RareSearch logo

BioLamina

50+ personnel
Headquartered in Chandler
Established in 2025
Website
Jacquelyn Braun profile

Jacquelyn Braun

πŸ‡ΊπŸ‡Έ United States

9.1

    Reviewed:

  • - Pharmacovigilance Services
  • - Ongoing
  • - Pharmaceutical Company

Highly effective pharmacovigilance services, ensured compliance.

The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.

Mr. Jerald Frami profile

Mr. Jerald Frami

πŸ‡¨πŸ‡­ Switzerland

9.4

    Reviewed:

  • - Health Technology Assessment
  • - 10 weeks September - November 2023
  • - Pharmaceutical Company

Thorough and insightful health technology assessment.

The health technology assessment was thorough and provided valuable insights that were critical to our decision-making process. The team demonstrated a deep understanding of the health economics involved and delivered a well-rounded analysis.

Ruby Bartell profile

Ruby Bartell

πŸ‡ΉπŸ‡· Turkey

8.9

    Reviewed:

  • - Medical Writing
  • - 5 weeks October - November 2023
  • - Biotech Company

Top-quality medical writing, clear and precise documents.

The medical writing services provided were of top quality. The documents were clear, precise, and tailored to meet the specific requirements of our regulatory submissions. The team's expertise was evident throughout the process.

Jeff Mraz profile

Jeff Mraz

πŸ‡¦πŸ‡Ί Australia

8.8

    Reviewed:

  • - Biostatistical Design
  • - 4 weeks May - June 2023
  • - Research Institution

Excellent biostatistical support, clear and actionable insights.

The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.

Hattie Nikolaus profile

Hattie Nikolaus

πŸ‡¬πŸ‡§ United Kingdom

6.5

    Reviewed:

  • - Regulatory Submission
  • - 8 weeks May - July 2024
  • - Pharmaceutical Company

Regulatory submission was incomplete, required additional work.

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.